REFERENCES
1. Lou H, Ma S, Zhao Y, et al. Sensitization patterns and minimum
screening panels for aeroallergens in self-reported allergic rhinitis in
China. Sci Rep. 2017;7(1):9286.
2. Zheng M, Wang X, Wang M, et al. Clinical characteristics of allergic
rhinitis patients in 13 metropolitan cities of China. Allergy .
2021;76(2):577-581.
3. Yang J, Wang W, Shen Z, et al. Efficacy and safety of Artemisia annua
sublingual immunotherapy in patients with seasonal allergic
rhinoconjunctivitis over two pollen seasons. Eur Arch
Otorhinolaryngol. 2023;280(11):4939-4947.
4. Lou H, Wang X, Wei Q, et al. Artemisia annua sublingual immunotherapy
for seasonal allergic rhinitis: A multicenter, randomized trial.World Allergy Organ J . 2020;13(9):100458.
5. Halken S, Roberts G, Valovirta E, Nolte H, Hulstrøm V, Blaiss MS.
Safety of timothy grass sublingual immunotherapy tablet in children:
pooled analyses of clinical trials. J Allergy Clin Immunol Pract.2020;8(4):1387-1393.e2.
6. Lou H, Huang Y, Ouyang Y, et al. Artemisia annua-sublingual
immunotherapy for seasonal allergic rhinitis: A randomized controlled
trial. Allergy . 2020;75(8):2026-2036.
Figure 1 Overview of study design and outcomes. Treatment began
around 16 weeks before pollen season, throughout a pollen season, and
continued 6 weeks after pollen season.
Figure 2 Efficacy and safety of Artemisia annua -SLIT in
children. (A) Time series of daily combined score of CSMRS and pollen
concentration [grey column: pollen counts; blue and black curves:
CSMRS of SLIT and placebo groups, respectively]. The charts below
represent the correlation between pollen concentration and daily CSMRS
in SLIT group (left) and placebo group (right) [grey shaded area: 95%
confidence level range]. CSMS (B) and CSMRS (C) compared between SLIT
and placebo groups in the 2019 pollen season.*P <0.05. (D) Incidence of most
frequently reported TRAEs in SLIT (>5% subjects) and
placebo groups. (E) Severity of most frequently reported TRAEs in SLIT
group. CSMS, combined score of medication and rhinitis symptom; CSMRS,
combined score of medication and rhinoconjunctivitis symptom; SLIT,
sublingual immunotherapy; TRAEs, treatment-related adverse events.